AstraZeneca PLC
corporate_fare Company Profile
AstraZeneca PLC (NYSE:AZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 59 items for AZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for AZN spans 6-K.
Recent high-impact activity:
- AstraZeneca Completes $2B Equity Investment in Summit Therapeutics
- AstraZeneca and Daiichi Sankyo Partner with Summit to Test Datroway Plus Ivonescimab in Phase III TNBC
- AstraZeneca and Daiichi Sankyo Team with Summit to Test Datroway-Ivonescimab Combo in TNBC
- AstraZeneca Invests $2B in Summit Therapeutics to Advance Ivonescimab-ADC Combinations
- EU Approves Trixeo as First Triple-Combination Asthma Therapy
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,087,754 shares in AZN as of the September 15, 2026 settlement, a 27.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 8, 2026, 43.4% of AZN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
AZN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.